The market will also face some challenges such as competition from biosimilars during the period.
One of the advantages of these novel ULTs is their superior efficacy and safety profile against their competitors.
GlobalData found that the two drugs made up 60% of Teva’s sales in Q3 2023.
The only permanent treatment option for blood conditions prior to this approval was a bone marrow transplant.
For the IBD market to continue to grow, it is critical for biologics entering the market to continue to show substantial efficacy over current biological and small-molecule therapies.
Give your business an edge with our leading industry insights.
Looking ahead, the Gaucher disease drug pipeline offers a combination of innovative products and therapies which emulate marketed treatments.
Odronextamab has demonstrated clinically meaningful efficacy and safety in patients with R/R FL and DLBCL.
Studies show that lowering the overall batch failure rate can reduce the cost of cell therapy manufacturing by millions of dollars per batch.
Both generic and innovator medicines can be falsified, ranging from expensive products for oncology to inexpensive products such as analgesics.
Psychedelic drugs such as those derived from psilocybin, lysergic acid diethylamide (LSD), and midomafetamine (MDMA), demonstrated promise in depression, anxiety disorder, and substance abuse.